Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]Fluorbetazine PET Imaging in Normal Cognition, MCI, and AD
NCT07764679Phase 3Recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 3 trial of fluorbetazine in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI). Started Jun 2025; status: recruiting.
02
Drugs
fluorbetazine
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07764679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764679.